This grant opportunity (PAR-25-070) from the NIH seeks to fund research into the mechanisms by which incretin mimetics impact cancer risk. Clinical trials are not allowed under this R21 funding mechanism. The CFDA number is 93.393.
Want the full details?
Sign up free to see the agency name, contact info, and the original bid posting link.